What Are GLP-1 Receptor Agonists?
Glucagon-like peptide-1 (GLP-1) receptor agonists represent one of the most significant breakthroughs in obesity medicine in decades. Originally developed for type 2 diabetes management, these medications have demonstrated remarkable efficacy for weight loss, fundamentally changing how clinicians approach obesity treatment.
GLP-1 is a naturally occurring incretin hormone released by intestinal L-cells after food intake. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and — critically for weight management — acts on hypothalamic receptors to reduce appetite and increase satiety.
Semaglutide: Mechanism and Evidence
Semaglutide (marketed as Wegovy for weight management and Ozempic for diabetes) is a modified GLP-1 analog with a half-life of approximately 7 days, enabling once-weekly subcutaneous dosing. The structural modification — a fatty acid side chain — allows it to bind to albumin, dramatically extending its duration of action compared to native GLP-1.
Key Clinical Trial Results
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program provided the landmark evidence:
- STEP 1: Participants receiving semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. One-third of participants lost more than 20% of their body weight.
- STEP 2: In patients with type 2 diabetes, semaglutide produced 9.6% weight loss — significant given that diabetes medications often cause weight gain.
- STEP 3: When combined with intensive behavioral therapy, weight loss reached 16.0%, demonstrating that medication and lifestyle modification have synergistic effects.
- STEP 5: Extended 2-year data showed sustained weight loss of 15.2%, addressing concerns about durability.
Beyond weight loss, semaglutide demonstrated cardiovascular benefits. The SELECT trial showed a 20% reduction in major adverse cardiovascular events (MACE) in overweight adults without diabetes, earning it a cardiovascular risk reduction indication.
Tirzepatide: The Dual-Agonist Approach
Tirzepatide (marketed as Mounjaro for diabetes, Zepbound for weight management) represents the next evolution — a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both incretin pathways simultaneously, tirzepatide achieves even greater weight loss than semaglutide alone.
SURMOUNT Trial Results
- SURMOUNT-1: At the highest dose (15 mg), participants lost an average of 22.5% of body weight over 72 weeks. More than one-third of participants lost 25% or more — approaching outcomes previously achievable only with bariatric surgery.
- SURMOUNT-2: In patients with type 2 diabetes, tirzepatide produced 14.7% weight loss at the 15 mg dose.
The GIP component appears to enhance fat oxidation and improve insulin sensitivity through mechanisms distinct from GLP-1 alone, potentially explaining the superior efficacy.
Patient Selection: Who Benefits Most?
Providers should consider GLP-1 therapy for patients who meet these criteria:
- BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)
- Failed prior attempts at lifestyle modification alone (diet and exercise for at least 6 months)
- No contraindications: Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or history of pancreatitis require careful evaluation
Pre-Treatment Assessment
Before initiating therapy, providers should obtain:
- Baseline metabolic panel (fasting glucose, HbA1c, lipid panel)
- Thyroid function tests
- Assessment of gastrointestinal history (gastroparesis, inflammatory bowel disease)
- Pregnancy test for women of childbearing age (GLP-1 RAs are contraindicated in pregnancy)
- Documentation of prior weight management attempts
Managing Side Effects
The most common side effects are gastrointestinal: nausea (40-44%), diarrhea (30%), vomiting (24%), and constipation (24%). These are typically dose-dependent, most pronounced during dose escalation, and tend to diminish over 4-8 weeks.
Best practices for minimizing GI side effects:
- Follow the recommended dose escalation schedule (do not rush to maintenance dose)
- Advise patients to eat smaller meals and avoid high-fat foods during titration
- Stay well hydrated
- Consider anti-nausea medication (ondansetron) for the first few weeks if needed
The Provider Opportunity
The GLP-1 weight loss market is projected to exceed $100 billion globally by 2030. For telehealth providers, this represents a significant clinical and business opportunity. Platforms like SendMyDrugs enable providers to offer these treatments through branded storefronts with compliant prescribing workflows, pharmacy fulfillment, and patient monitoring — all without the overhead of traditional practice infrastructure.
Providers who invest in understanding the clinical nuance of GLP-1 therapy, patient selection, and long-term management will be best positioned to serve the growing demand while delivering excellent patient outcomes.